Conatus Pharmaceuticals Inc. (CNAT) Rating Lowered to Hold at Zacks Investment Research
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Conatus’ third-quarter results were encouraging with the company reporting a narrower-than-expected loss. The company’s progress with its lead candidate, emricasan, has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis under the ENCORE program. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Given that there are currently no approved therapies for NASH and the significant market opportunity, the company’s efforts to develop emricasan are promising. Moreover, the company’s plans to evaluate partnership opportunities for emricasan outside North America could be rewarding, if successful. However, emricasan is still several years away from entering the market, if at all. Any development/regulatory setback could hamper the company’s prospects and impact the stock adversely.”
Several other equities analysts also recently commented on CNAT. Brean Capital set a $7.00 price target on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 5th. FBR & Co reiterated an “outperform” rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a report on Tuesday, August 30th. Stifel Nicolaus cut their price target on shares of Conatus Pharmaceuticals from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, November 9th. Finally, JMP Securities reiterated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Wednesday, November 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $8.54.
Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 2.00 on Monday. Conatus Pharmaceuticals has a 52 week low of $1.40 and a 52 week high of $4.05. The company’s market cap is $44.14 million. The firm’s 50 day moving average is $1.89 and its 200-day moving average is $2.05.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.03. During the same quarter in the prior year, the company earned ($0.31) EPS. On average, analysts predict that Conatus Pharmaceuticals will post ($1.28) earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its stake in shares of Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,668 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock valued at $925,000 after buying an additional 15,300 shares during the last quarter. AXA boosted its stake in shares of Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock valued at $2,237,000 after buying an additional 14,939 shares during the last quarter. KCG Holdings Inc. acquired a new stake in shares of Conatus Pharmaceuticals during the third quarter valued at $135,000. Finally, Courage Capital Management LLC acquired a new stake in shares of Conatus Pharmaceuticals during the third quarter valued at $200,000. 22.89% of the stock is owned by institutional investors.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.